clinical trial · NCT07172919
A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation
Amgen·phase2·recruiting·n = 14
Advanced Solid TumorsSotorasibPanitumumab
brief summary
The primary objective of the study is to evaluate the safety and tolerability of the continuation of sotorasib with or without panitumumab and/or other anti-cancer therapies in participants continuing to derive benefit in Amgen-sponsored protocols.
started
Jan 2, 2026
primary completion
Jan 2, 2028
completion
Jan 2, 2028
last updated
Apr 9, 2026
official title
A Rollover Study of Sotorasib With or Without Panitumumab for the Treatment of Cancer Subjects With KRAS p.G12C Mutation Previously Treated in an Amgen-Sponsored Study
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol